Atopic dermatitis
Conditions
Interventions
Experimental Group:Wushezhiyang pill
Control group:Placebo
Sponsors
Shanghai Dermatology Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: In accordance with the williams diagnostic criteria (" Chinese Guidelines for the diagnosis and Treatment of atopic Dermatitis "2020 edition); According to the syndrome differentiation of traditional Chinese medicine it was blood deficiency and wind dryness syndrome (2013 edition of the Expert Consensus on the diagnosis and Treatment of Atopic Dermatitis in Chinese Medicine). Baseline atopic dermatitis score (SCORAD) =50; Baseline body surface area (BSA) =10%; Age: 18-65 years old both sexes; Consent to participate in this clinical trial.
Exclusion criteria
Exclusion criteria: Patients with other skin conditions that cause pruritus; Patients with serious cardiovascular and cerebrovascular diseases or tumors; Abnormal laboratory indicators: serum creatinine (SCr) exceeded (not included) the upper limit of normal value; The levels of alanine aminotransferase (ALT) aspartate aminotransferase (AST) alkaline phosphatase (ALP) and ?-glutamyl transpeptidase (GGT) were more than 1.5 times of the upper limit of normal (not included); Total bilirubin (TBIL) was more than 1.5 times the upper limit of normal value (not included); Patients who were treated with systemic or topical corticosteroids (including low - medium - high - and super - potent corticosteroids) and immunosuppressive agents within 2 weeks before screening; Patients who used biological agents within 3 months before screening; Patients who had used traditional Chinese medicine (TCM) acupuncture and other TCM treatments that were judged by the researchers to affect the efficacy evaluation within 1 week before screening; Patients allergic to the trial drug or its components; Patients who are pregnant lactating or have recently planned to have children; Participants who participated in clinical trials of other medical facilities or drugs within 3 months before screening; Subjects deemed unsuitable for the study by the investigator.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| SCORAD; | — |
Secondary
| Measure | Time frame |
|---|---|
| Rate of recurrence;Dosage of levocetirizine tablets;PP-NRS;DLQI;IGA;POEM; | — |
Countries
China
Contacts
Public ContactRuiping Wang
Shanghai Dermatology Hospital
Outcome results
None listed